PR Newswire
BEIJING
, Aug. 15, 2025 /PRNewswire/ — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the second quarter ended June 30, 2025.
Second Quarter 202
5 Financial Highlights
- Total revenues were RMB378.7 million (US$52.9 million[1]), compared with RMB407.4 million in the corresponding period of 2024. The aesthetic treatment services revenues were RMB144.4 million (US$20.2 million), compared with RMB27.4 million in the corresponding period of 2024, exceeding the high end of guidance.
- Net loss attributable to So-Young International Inc. was RMB36.0 million (US$5.0 million), compared with net income attributable to So-Young International Inc. of RMB18.9 million in the same period of 2024.
- Non-GAAP net loss attributable to So-Young International Inc.[2] was RMB30.5 million (US$4.3 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB22.2 million in the same period of 2024.
Second Quarter 2025 Operational Highlights
- The aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB303.9 million, compared with RMB427.8 million in the same period of 2024.
- Number of verified treatment visits to the branded aesthetic centers for the quarter reached over 67,400, compared with approximately 14,000 in the same period of 2024. The number of verified paid aesthetic treatments performed surpassed 154,500, compared with approximately 27,600 in the same period of 2024.
- The number of active users, defined as those who visited branded aesthetic centers at least once during the 12-month period ended on June 30, 2025, exceeded 100,400, compared with approximately 16,000 users during the corresponding period in 2024.
- As of June 30, 2025, So-Young had 29 fully operational branded aesthetic centers in nine major cities, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing and Changsha. Among them, 25 centers have achieved positive monthly operating cash flow. The following table shows the revenues generated by So-Young aesthetic centers, categorized by their phase of development:
|
|
|
|
|
|
Ramp-up (0-3 months) |
9 |
23,554,000 |
2,617,000 |
|
Growth (4-12 months) |
14 |
89,644,000 |
6,403,000 |
|
Maturity (over 12 months) |
6 |
31,192,000 |
5,199,000 |
- The number of institutions So-Young served with supply chain solutions for injectables grew to over 1,600 as of June 30, 2025. Shipments of Elasty injectable products reached approximately 39,100 units in the second quarter of 2025, compared with 43,200 in the same period of 2024.
|
|
|
|
Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “During the second quarter, our branded aesthetic centers became the largest contributor to revenue for the first time, a significant milestone in our transformation strategy. With 29 aesthetic centers now in operation across China, we have solidified our position as the country’s leading light medical aesthetics brand. This achievement highlights the strength of our vertically integrated strategy and continued focus on offering standardized aesthetic services. Through ongoing operational enhancements, expanding portfolio of proprietary products, and brand-enhancing initiatives that deepen consumer engagement, we have substantially increased customer trust and loyalty. As we enter the next phase of growth, we are focused on further scaling our aesthetic center network and broadening our market presence, unlocking greater long-term value for customers, partners, and shareholders.”
Mr. Hui Zhao, Chief Financial Officer of So-Young, added, “In the second quarter, we saw further improvements in both the scale and quality of our aesthetic centers. With a target of operating 50 centers by year-end, our near-term financial results will continue to reflect ongoing investments to support the long-term sustainable growth and consolidate our market leading position.”
Second Quarter 2025 Financial Results
Revenues
Total revenues were RMB378.7 million (US$52.9 million), a decrease of 7.0% from RMB407.4 million in the same period of 2024. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.
- Aesthetic treatment services[3] revenues were RMB144.4 million (US$20.2 million), an increase of 426.1% from RMB27.4 million in the same period of 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.
- Information and reservation services revenues were RMB135.2 million (US$18.9 million), a decrease of 35.6% from RMB209.7 million in the same period of 2024. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.
- Sales of medical products and maintenance services were RMB76.0 million (US$10.6 million), a decrease of 28.1% from RMB105.8 million in the same period of 2024, primarily due to a decrease in the order volume of medical products.
-
Other
services revenues were RMB23.2 million (US$3.2 million), a decrease of 64.0% from RMB64.4 million in the same period of 2024, primarily due to a decrease in So-Young Prime.
|
|
|
The revenue generated from aesthetic treatment services was previously reported in line item of information services and others. The revenue generated from information and reservation services and other services for the second quarter of 2024 have also been retrospectively updated. The amount reclassified from previous line item information services and others to aesthetic treatment services and information and reservation services is RMB27.4 million and RMB187.4 million for the second quarter of 2024, respectively. |
Cost of Revenues
Cost of revenues was RMB184.6 million (US$25.8 million), an increase of 19.0% from RMB155.1 million in the second quarter of 2024. The increase was primarily due to business expansion of the branded aesthetic centers. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with RMB0.2 million in the corresponding period of 2024.
- Cost of aesthetic treatment services were RMB109.4 million (US$15.3 million), an increase of 405.5% from RMB21.6 million in the second quarter of 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.
- Cost of information and reservation services[4] were RMB16.7 million (US$2.3 million), a decrease of 47.4% from RMB31.7 million in the second quarter of 2024. The decrease was in line with the decrease in revenue generated from information and reservation services.
- Cost of medical products sold and maintenance services were RMB39.5 million (US$5.5 million), a decrease of 25.8% from RMB53.2 million in the second quarter of 2024. The decrease was primarily due to a decrease in costs associated with the sales of medical products.
- Cost of other services were RMB19.0 million (US$2.7 million), a decrease of 60.8% from RMB48.5 million in the second quarter of 2024. The decrease was primarily due to a decrease in costs associated with So-Young Prime.
Operating Expenses
Total operating expenses were RMB241.3 million (US$33.7 million), a decrease of 1.8% from RMB245.6 million in the second quarter of 2024.
- Sales and marketing expenses were RMB131.3 million (US$18.3 million), a decrease of 0.7% from RMB132.3 million in the second quarter of 2024. The decrease was primarily attributable to the decrease of payroll cost. Sales and marketing expenses included share-based compensation expenses of RMB0.6 million (US$0.1 million) in the second quarter of 2025, compared with RMB0.2 million in the corresponding period of 2024.
- General and administrative expenses were RMB78.8 million (US$11.0 million), an increase of 11.3% from RMB70.8 million in the second quarter of 2024. The increase was primarily due to an increase in payroll costs associated with the expansion of administrative employees to support our business upgrade and new strategic businesses. General and administrative expenses included share-based compensation expenses of RMB4.3 million (US$0.6 million) in the second quarter of 2025, compared with RMB2.0 million in the corresponding period of 2024.
- Research and development expenses were RMB31.2 million (US$4.4 million), a decrease of 26.6% from RMB42.5 million in the second quarter of 2024. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.5 million (US$0.1 million) in the second quarter of 2025, compared with RMB0.8 million in the corresponding period of 2024.
|
|
Income Tax (Expenses)/Benefits
Income tax expenses were RMB1.9 million (US$0.3 million), compared with income tax benefits of RMB2.6 million in the same period of 2024.
Net (Loss)/Income Attributable to So-Young International Inc.
Net loss attributable to So-Young International Inc. was RMB36.0 million (US$5.0 million), compared with a net income attributable to So-Young International Inc. of RMB18.9 million in the second quarter of 2024.
Non-GAAP Net (Loss)/Income Attributable to So-Young International Inc.
Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, was RMB30.5 million (US$4.3 million), compared with RMB22.2 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2024.
Basic and Diluted (Loss)/Earnings per ADS
Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.35(US$0.05) and RMB0.35(US$0.05), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2024.
Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments
As of June 30, 2025, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB998.6 million (US$139.4 million), compared with RMB1,253.2 million as of December 31, 2024.
Business Outlook
For the third quarter of 2025, So-Young expects aesthetic treatment services revenues to be between RMB150.0 million (US$20.9 million) and RMB170.0 million (US$23.7 million), representing a 230.5% to 274.6% increase from the same period in 2024. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.
Non-GAAP Financial Measures
To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income/(loss) attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.
Conference Call Information
So-Young’s management will hold an earnings conference call on Friday, August 15, 2025, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:
|
International: |
+1-412-902-4272 |
|
Mainland China: |
4001-201203 |
|
US: |
+1-888-346-8982 |
|
Hong Kong: |
+852-301-84992 |
|
Passcode: |
So-Young International Inc. |
A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, August 22, 2025. The dial-in details are:
|
International: |
+1-412-317-0088 |
|
US: |
+1-877-344-7529 |
|
Passcode: |
1137391 |
Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.
For more information, please contact:
So-Young
Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: [email protected]
Christensen
In China
Ms. Charlie Chi
Phone: +86-10-5900-1548
E-mail: [email protected]
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|
|
|||
|
|
|
|
|||
|
|
|
|
|||
|
|
|||||
|
Current assets: |
|||||
|
Cash and cash equivalents |
587,749 |
380,907 |
53,173 |
||
|
Restricted cash and term deposits |
66,367 |
84,996 |
11,865 |
||
|
Trade receivables |
98,774 |
78,199 |
10,916 |
||
|
Inventories |
151,754 |
242,415 |
33,840 |
||
|
Receivables from online payment platforms |
24,255 |
23,218 |
3,241 |
||
|
Amounts due from related parties |
1,218 |
2,620 |
366 |
||
|
Term deposits and short-term investments |
599,041 |
532,696 |
74,361 |
||
|
Prepayment and other current assets |
195,202 |
250,557 |
34,976 |
||
|
|
|
|
|
||
|
Non-current assets: |
|||||
|
Long-term investments |
280,281 |
277,642 |
38,757 |
||
|
Intangible assets |
126,615 |
126,561 |
17,667 |
||
|
Goodwill |
684 |
684 |
95 |
||
|
Property and equipment, net |
155,352 |
196,252 |
27,396 |
||
|
Deferred tax assets |
84,950 |
83,805 |
11,699 |
||
|
Operating lease right-of-use assets |
162,764 |
196,677 |
27,455 |
||
|
Other non-current assets |
200,152 |
172,937 |
24,141 |
||
|
|
|
|
|
||
|
|
|
|
|
||
|
|
|||||
|
Current liabilities: |
|||||
|
Short-term borrowings |
69,771 |
59,801 |
8,348 |
||
|
Taxes payable |
61,862 |
46,623 |
6,508 |
||
|
Contract liabilities |
76,579 |
70,362 |
9,822 |
||
|
Salary and welfare payables |
111,396 |
58,883 |
8,220 |
||
|
Amounts due to related parties |
477 |
569 |
79 |
||
|
Accrued expenses and other current liabilities |
265,216 |
330,237 |
46,101 |
||
|
Operating lease liabilities-current |
44,905 |
58,649 |
8,187 |
||
|
|
|
|
|
||
|
Non-current liabilities: |
|||||
|
Operating lease liabilities-non current |
125,200 |
145,238 |
20,274 |
||
|
Deferred tax liabilities |
19,758 |
17,973 |
2,509 |
||
|
Other non-current liabilities |
1,264 |
1,736 |
242 |
||
|
|
|
|
|
||
|
|
|
|
|
||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
Treasury stock |
(376,690) |
(391,944) |
(54,713) |
||
|
Class A ordinary shares (US$0.0005 par value; 750,000,000 |
253 |
254 |
35 |
||
|
Class B ordinary shares (US$0.0005 par value; 20,000,000 |
37 |
37 |
5 |
||
|
Additional paid-in capital |
3,069,799 |
3,057,951 |
426,873 |
||
|
Statutory reserves |
40,552 |
40,552 |
5,661 |
||
|
Accumulated deficit |
(926,390) |
(995,567) |
(138,976) |
||
|
Accumulated other comprehensive income |
31,560 |
27,977 |
3,905 |
||
|
|
|
|
|
||
|
Non-controlling interests |
119,609 |
120,835 |
16,868 |
||
|
|
|
|
|
||
|
|
|
|
|
||
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
|
|||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
|
||||||||||||
|
Aesthetic treatment services |
27,444 |
144,390 |
20,156 |
42,615 |
243,217 |
33,952 |
||||||
|
Information and reservation services |
209,734 |
135,172 |
18,869 |
386,109 |
256,797 |
35,847 |
||||||
|
Sales of medical products and maintenance services |
105,808 |
76,036 |
10,614 |
192,278 |
131,626 |
18,374 |
||||||
|
Other services |
64,394 |
23,150 |
3,232 |
104,660 |
44,378 |
6,195 |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
||||||||||||
|
Cost of aesthetic treatment services |
(21,637) |
(109,370) |
(15,267) |
(34,032) |
(189,634) |
(26,472) |
||||||
|
Cost of information and reservation services |
(31,744) |
(16,705) |
(2,332) |
(63,261) |
(40,002) |
(5,584) |
||||||
|
Cost of medical products sold and maintenance services |
(53,198) |
(39,491) |
(5,513) |
(96,291) |
(69,916) |
(9,760) |
||||||
|
Cost of other services |
(48,472) |
(18,992) |
(2,651) |
(78,782) |
(36,421) |
(5,084) |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||||||
|
|
||||||||||||
|
Sales and marketing expenses |
(132,308) |
(131,333) |
(18,333) |
(245,564) |
(229,209) |
(31,996) |
||||||
|
General and administrative expenses |
(70,799) |
(78,786) |
(10,998) |
(155,752) |
(138,070) |
(19,274) |
||||||
|
Research and development expenses |
(42,498) |
(31,177) |
(4,352) |
(82,089) |
(63,286) |
(8,834) |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||||||
|
|
||||||||||||
|
Investment income, net |
788 |
884 |
123 |
2,887 |
99 |
14 |
||||||
|
Interest income, net |
11,718 |
7,948 |
1,109 |
24,031 |
14,973 |
2,090 |
||||||
|
Exchange gains |
16 |
701 |
98 |
410 |
726 |
101 |
||||||
|
Share of losses of equity method investee |
(3,733) |
(1,012) |
(141) |
(7,729) |
(3,454) |
(482) |
||||||
|
Others, net |
2,039 |
5,663 |
791 |
5,319 |
10,497 |
1,465 |
||||||
|
|
|
|
|
|
|
|
||||||
|
Income tax benefits/(expenses) |
2,571 |
(1,877) |
(262) |
5,128 |
(272) |
(38) |
||||||
|
|
|
|
|
|
|
|
||||||
|
Net income attributable to noncontrolling interests |
(1,182) |
(1,240) |
(173) |
(2,236) |
(1,226) |
(171) |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
|
|||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
|
||||||||||||
|
Net earnings/(loss) per ordinary share attributable to ordinary shareholder – |
0.24 |
(0.46) |
(0.06) |
(0.03) |
(0.88) |
(0.12) |
||||||
|
Net earnings/(loss) per ordinary share attributable to ordinary shareholder – |
0.24 |
(0.46) |
(0.06) |
(0.03) |
(0.88) |
(0.12) |
||||||
|
Net earnings/(loss) per ADS attributable to ordinary shareholders – basic (13 |
0.18 |
(0.35) |
(0.05) |
(0.02) |
(0.68) |
(0.09) |
||||||
|
Net earnings/(loss) per ADS attributable to ordinary shareholders – diluted (13 |
0.18 |
(0.35) |
(0.05) |
(0.02) |
(0.68) |
(0.09) |
||||||
|
Weighted average number of ordinary shares used in computing |
79,586,926 |
77,826,404 |
77,826,404 |
79,569,190 |
78,194,634 |
78,194,634 |
||||||
|
Weighted average number of ordinary shares used in computing |
79,899,412 |
77,826,404 |
77,826,404 |
79,569,190 |
78,194,634 |
78,194,634 |
||||||
|
|
||||||||||||
|
Cost of revenues |
(229) |
(124) |
(17) |
(174) |
(154) |
(21) |
||||||
|
Sales and marketing expenses |
(184) |
(598) |
(83) |
(237) |
(728) |
(102) |
||||||
|
General and administrative expenses |
(2,015) |
(4,286) |
(598) |
(26,468) |
(5,690) |
(794) |
||||||
|
Research and development expenses |
(817) |
(487) |
(68) |
(1,660) |
(580) |
(81) |
||||||
|
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted. |
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
|
|||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
||||||
|
Add back: Share-based compensation expenses |
3,245 |
5,495 |
766 |
28,539 |
7,152 |
998 |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||||||
|
Add back: Share-based compensation expenses |
3,245 |
5,495 |
766 |
28,539 |
7,152 |
998 |
||||||
|
|
|
|
|
|
|
|
||||||
View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-second-quarter-2025-financial-results-302530934.html
SOURCE So-Young International Inc.
